GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Savara Inc (STU:YB4P) » Definitions » Cyclically Adjusted Price-to-FCF

Savara (STU:YB4P) Cyclically Adjusted Price-to-FCF : (As of May. 31, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Savara Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Savara Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Savara's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Savara Cyclically Adjusted Price-to-FCF Chart

Savara Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Savara Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Savara's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Savara's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Savara's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Savara's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Savara's Cyclically Adjusted Price-to-FCF falls into.



Savara Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Savara's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Savara's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.104/131.7762*131.7762
=-0.104

Current CPI (Mar. 2024) = 131.7762.

Savara Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -3.162 100.560 -4.144
201409 -2.378 100.428 -3.120
201412 -2.350 99.070 -3.126
201503 -3.009 99.621 -3.980
201506 -3.291 100.684 -4.307
201509 -3.158 100.392 -4.145
201512 7.586 99.792 10.017
201603 -4.004 100.470 -5.252
201606 6.831 101.688 8.852
201609 -0.944 101.861 -1.221
201612 -0.570 101.863 -0.737
201703 -0.896 102.862 -1.148
201706 -0.494 103.349 -0.630
201709 -0.286 104.136 -0.362
201712 -0.274 104.011 -0.347
201803 -0.251 105.290 -0.314
201806 -0.283 106.317 -0.351
201809 -0.218 106.507 -0.270
201812 -0.258 105.998 -0.321
201903 -0.269 107.251 -0.331
201906 -0.298 108.070 -0.363
201909 -0.248 108.329 -0.302
201912 -0.204 108.420 -0.248
202003 -0.258 108.902 -0.312
202006 -0.117 108.767 -0.142
202009 -0.095 109.815 -0.114
202012 -0.167 109.897 -0.200
202103 -0.105 111.754 -0.124
202106 -0.066 114.631 -0.076
202109 -0.050 115.734 -0.057
202112 -0.054 117.630 -0.060
202203 -0.050 121.301 -0.054
202206 -0.058 125.017 -0.061
202209 -0.054 125.227 -0.057
202212 -0.053 125.222 -0.056
202303 -0.074 127.348 -0.077
202306 -0.063 128.729 -0.064
202309 -0.075 129.860 -0.076
202312 -0.077 129.419 -0.078
202403 -0.104 131.776 -0.104

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Savara  (STU:YB4P) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Savara Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Savara's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Savara (STU:YB4P) Business Description

Industry
Traded in Other Exchanges
Address
6836 Bee Cave Road, Building I, Suite 205, Austin, TX, USA, 78746
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Savara (STU:YB4P) Headlines

No Headlines